Pudgy Penguins: Is a new bull run setting up? Examining…

ambcryptoОпубліковано о 2025-10-20Востаннє оновлено о 2025-10-21

Key Takeaways 

How does PENGU’s short-term trend look?

It confirms a shift toward bullish momentum as buyers reclaim control above $0.021 levels.

What do recent exchange outflows and whale activity suggest?

Outflows totaling $863K and renewed whale accumulation indicate reduced sell pressure and growing confidence.


The market structure of Pudgy Penguins [PENGU] has started to show promising signs of recovery as the TD Sequential buy signal gets validated, aligning with consistent exchange outflows and renewed whale accumulation. 

The confluence of technical and on-chain metrics suggests momentum is shifting in favor of buyers.

Price movements consolidating within a bullish pattern that could soon trigger a breakout toward higher Fibonacci targets.

An explosive upside toward Fibonacci targets

A clear cup-and-handle formation is visible on the weekly chart, reflecting gradual recovery momentum after a prolonged correction. 

The handle consolidation appears nearly complete, positioning PENGU for a potential breakout above the 1.0 Fib level at $0.0218. 

If confirmed, the Fibonacci extensions at 1.618 ($0.0305) and 2.618 ($0.0447) could serve as the next price targets. 

Additionally, the liquidation heatmap shows heavy clusters between $0.023 and $0.0238, which could spark a short squeeze once liquidity is triggered.

Such a move would likely strengthen the bullish narrative across spot and derivatives markets.

PENGU price actionPENGU price action

Source: TradingView

Investors pull $863K from trading platforms

Spot flow data reveals a net outflow of $863K on the 21st of October, confirming that holders were moving tokens off exchanges. This trend reduces sell pressure and reflects growing investor confidence. 

Interestingly, the magnitude of these outflows has increased alongside the recent TD Sequential confirmation, reinforcing the notion that accumulation is underway. 

Moreover, historical data shows that similar withdrawal spikes often precede upward continuation patterns. 

However, sustaining this momentum will require consistent buying from both retail and institutional segments.

Source: CoinGlass

Large holders return to Pudgy Penguins

Data from CryptoQuant showed an uptick in large whale order sizes, signaling renewed institutional and high-net-worth participation. 

This pattern, marked by clusters of green whale orders, mirrors previous accumulation zones that preceded significant uptrends. 

The alignment between on-chain accumulation and technical breakout potential creates a favorable setup for a rally. 

However, continuous accumulation remains key for validating this bullish outlook, especially as PENGU approaches resistance near $0.023.

PENGU Spot Average Order SizePENGU Spot Average Order Size

Source: CryptoQuant

Is PENGU ready for a decisive breakout?

The convergence of bullish signals across both technical and on-chain metrics strengthens PENGU’s short-term recovery prospects. 

A confirmed breakout above $0.023 could open the path toward $0.03 and beyond, supported by consistent whale buying and reduced exchange supply. 

While momentum looks promising, sustained accumulation and breakout confirmation remain essential to validate the next major rally.

Share

Пов'язані матеріали

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

On August 19, J.P. Morgan (JPM) published a research report analyzing Moderna's recent Phase III trial success for its Individualized Neoantigen Therapy (INT), developed in partnership with Merck, in adjuvant melanoma. The trial met its primary endpoint of significantly improved recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. While JPM acknowledged the strong clinical value of these results, particularly the prevention of distant metastasis, the bank stated that this success was widely anticipated, with an 85% prior probability of success, and is already reflected in Moderna's current market valuation. Following the announcement, Moderna's stock rose in pre-market trading. However, JPM maintained its Underweight rating and $40 price target, implying approximately 36% downside from the current price of ~$63. The core rationale is that the success in adjuvant melanoma, a relatively small market in immuno-oncology, is fully priced in. Moderna's future valuation hinges entirely on INT's ability to demonstrate similar efficacy across broader cancer indications. JPM's valuation model incorporates only a modest risk-adjusted value (~$3/share) for the melanoma approval. Approximately $15/share of its target price is attributed to INT's potential in other cancer types. The report identifies upcoming data readouts in non-melanoma cancers (e.g., lung, head & neck, renal) as the critical variable that will determine the platform's ultimate value. Upside risks include better-than-expected data in these new indications, while downside risks involve clinical failures, regulatory delays, or commercial underperformance. In conclusion, JPM views the pre-market stock move as driven by short covering and trading sentiment rather than a fundamental re-rating. The bank remains bearish, arguing that Moderna must now prove INT's efficacy as a platform technology beyond melanoma to justify its current market cap.

marsbit8 хв тому

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

marsbit8 хв тому

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

The article discusses the U.S. Treasury's recent direct intervention to suppress long-term bond yields through buyback operations. While distinct from traditional Yield Curve Control (YCC), this move is interpreted as direct government intervention in its own financing costs. The author emphasizes the short-term tactical nature of this action and contrasts it with the Federal Reserve's upcoming, potentially divergent, policy stance at Jackson Hole. The core issue is framed as a long-term U.S. strategic dilemma: managing high deficit levels. The analysis argues that deficit reduction cannot realistically come from spending cuts or traditional industries, but must rely on achieving higher economic growth driven by technological breakthroughs. Current monetary tightening, while possibly curbing yields and inflation in the short term, is seen as potentially counterproductive to this necessary long-term investment in technology and supply chain resilience. The piece draws historical parallels, placing the current intervention between the 2000-2002 Treasury buybacks (for liquidity) and larger-scale Fed-led "Operation Twist" maneuvers. The effectiveness of the Treasury's action is deemed limited without Federal Reserve cooperation, which would signify a more significant policy shift. Ultimately, the author views such technical, bureaucratic interventions as treating symptoms rather than the underlying disease of the U.S. economy's structural challenges and "K-shaped" divergence. The conclusion suggests that sustained yield suppression by the Fed, combined with specific geopolitical outcomes, could serve as a catalyst for a more profound discussion on broader U.S. and dollar trajectory.

marsbit8 хв тому

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

marsbit8 хв тому

Торгівля

Спот
活动图片